The pharmacotherapeutics of sarcoidosis

References

• James DG, Sharma OP. From Hutchinson to now: a historical glimpse. Curr Opin Pulm Med. 2002;8(5):416–423.
   Google Scholar
• Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021. DOI:10.1183/13993003.04079-2020
   Google Scholar
• Melani AS, Bigliazzi C, Cimmino FA, et al. Review of sarcoidosis treatment for pulmonologists. Pulm Ther. 2021. DOI:10.1007/s41030-021-00160-x
   Google Scholar
• Herzog HL, Hughes MT, Gentles MJ, et al. Microbiological transformation of steroids—X: 1-dehydro analogs of cortical steroids. ScienceDirect. 1962;18(5):581–589.
   Google Scholar
• Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin. 1949;24(8):181–197.
   Google Scholar
• Siltzbach LE, Posner A, Medine MM. Cortisone therapy in sarcoidosis; effect in a case with virtual blindness. J Am Med Assoc. 1951;147(10):927–929.
   Google Scholar
• Sones M, Israel HL, Dratman MB, et al. Effect of cortisone in sarcoidosis. N Engl J Med. 1951;244(6):209–213.
   Google Scholar
• James DG, Carstairs LS, Trowell J, et al. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967;2(7515):526–528.
   Google Scholar
• Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973;107(4):609–614.
   Google Scholar
• Silva M, Nunes H, Valeyre D, et al. Imaging of Sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):45–53.
   Google Scholar
• Rizzato G, Riboldi A, Imbimbo B, et al. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis. Respir Med. 1997;91(8):449–460.
   Google Scholar
• Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51(3):238–247.
   Google Scholar
• Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis. 1979;60(4):215–221.
   Google Scholar
• Zaki MH, Lyons HA, Leilop L, et al. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med. 1987;87(9):496–499.
   Google Scholar
• Pietinalho A, Tukiainen P, Haahtela T, et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest. 1999;116(2):424–431.
   Google Scholar
• Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655–670.
   Google Scholar
• Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56(1):23–46.
   Google Scholar
• Du Bois RM. Corticosteroids in sarcoidosis: friend or foe? Eur Respir J. 1994;7(7):1203–1209.
   Google Scholar
• Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29(155). DOI:10.1183/16000617.0146-2019
   Google Scholar
• James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol. 2018;11(7):677–687.
   Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537.
   Google Scholar
• Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med. 2008;102(1):1–9.
   Google Scholar
• Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs. 2006;24(1):37–77.
   Google Scholar
• Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301–307.
   Google Scholar
• Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med. 1968;69(6):1247–1248.
   Google Scholar
• Clinical and research information on drug-induced liver injury. LiverTox; 2012.
   Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–66.
   Google Scholar
• Goljan-Geremek A, Bednarek M, Franczuk M, et al. Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study. Pneumonol Alergol Pol. 2014;82(6):518–533.
   Google Scholar
• Nagai S, Yokomatsu T, Tanizawa K, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med. 2014;53(23):2761.
   Google Scholar
• Baughman RP, Lower EE, Ingledue R, et al. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(1):26–33.
   Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–812.
   Google Scholar
• Fang C, Zhang Q, Wang N, et al. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(3):217–227.
   Google Scholar
• Fairbanks LD, Ruckemann K, Qiu Y, et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J. 1999;342(Pt 1):143–152.
   Google Scholar
• Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19(5):545–561.
   Google Scholar
• Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med. 2003;163(5):615–620.
   Google Scholar
• Tolman KG, Clegg DO, Lee RG, et al. Methotrexate and the liver. J Rheumatol Suppl. 1985;12(Suppl 12):29–34.
   Google Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155(8):846–851.
   Google Scholar
• Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14(5):1117–1122.
   Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5):1095–1105.
   Google Scholar
• Lawson DH, Lovatt GE, Gurton CS, et al. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev. 1984;3(3):161–171.
   Google Scholar
• Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005;80(2 Suppl):S254–64.
   Google Scholar
• Jiyad Z, Olsen CM, Burke MT, et al. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transplant. 2016;16(12):3490–3503.
   Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, et al., American Gastroenterological Association Institute Clinical Guidelines C. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–834.
   Google Scholar
• Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995;275(2):1043–1049.
   Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):43–48.
   Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–1150.
   Google Scholar
• Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93(3):198–208.
   Google Scholar
• Le V, Crouser ED. Potential immunotherapies for sarcoidosis. Expert Opin Biol Ther. 2018;18(4):399–407.
   Google Scholar
• [package insert]. Sanofi-Aventis B, NJ. Leflunomide 2015; [ cited 2021 Jul 20]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020905s022lbl.pdf
   Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   Google Scholar
• Florey HW, Jennings MA, Gilliver K, et al. Mycophenolic acid; an antibiotic from Penicillium brevicompactum Dlerckx. Lancet. 1946;1(6385):46–49.
   Google Scholar
• Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348(9038):1357–1359.
   Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118.
   Google Scholar
• McMurray RW, Harisdangkul V. Mycophenolate mofetil: selective T cell inhibition. Am J Med Sci. 2002;323(4):194–196.
   Google Scholar
• Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987;17(6):962–971.
   Google Scholar
• Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329–335.
   Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998;352(9121):35–36.
   Google Scholar
• Hamzeh N, Voelker A, Forssen A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108(11):1663–1669.
   Google Scholar
• Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration. 2013;86(5):376–383.
   Google Scholar
• Shaw LM, Korecka M, Aradhye S, et al. Scientific principles for mycophenolic acid therapeutic drug monitoring. Transplant Proc. 1998;30(5):2234–2236.
   Google Scholar
• Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4(2):237–243
   Google Scholar
• Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica. 2007;92(8):1029–1036.
   Google Scholar
• Mercadal L, Foltz V, Isnard-Bagnis C, et al. Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient. Transplant Proc. 2005;37(10):4241–4243.
   Google Scholar
• Waiser J, Schotschel R, Budde K, et al. Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. Am J Kidney Dis. 2000;35(3):E12.
   Google Scholar
• Wallace DJ. The history of antimalarials. Lupus. 1996;5(Suppl 1):S2–3.
   Google Scholar
• Ben-Zvi I, Kivity S, Langevitz P, et al. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42(2):145–153.
   Google Scholar
• Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951;2(6687):755–758.
   Google Scholar
• Shaffer B, Cahn MM, Levy EJ. Sarcoidosis apparently cured by quinacrine (atabrine) hydrochloride. AMA Arch Derm Syphilol. 1953;67(6):640–641.
   Google Scholar
• Klauder JV. Sarcoid of the eyelids, conjunctiva, and uveal tract treated with quinacrine hydrochloride (atabrine dihydrochloride). AMA Arch Derm Syphilol. 1953;68(4):474.
   Google Scholar
• Söderstrom N. Two cases of sarcoidosis treated with mepacrine. J Occup Environ Med. 1961;3(8):399.
   Google Scholar
• Morse SI, Cohn ZA, Hirsch JG, et al. The treatment of sarcoidosis with chloroquine. Am J Med. 1961;30:779–784.
   Google Scholar
• Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl. 1964;425:302–308.
   Google Scholar
• Chloroquine in the Treatment of Sarcoidosis. A report from the research committee of the British Tuberculosis Association. Tubercle. 1967;48(4):257–272.
   Google Scholar
• Zic JA, Horowitz DH, Arzubiaga C, et al. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol. 1991;127(7):1034–1040.
   Google Scholar
• Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160(1):192–197.
   Google Scholar
• Brodthagen H. Chloroquine in pulmonary sarcoidosis. Lancet. 1968;1(7552):1157.
   Google Scholar
• Browning D. Pharmacology of chloroquine and hydroxychloroquine. Hydroxychloroquine Chloroquine Retinopathy. 2014;4:35–63.
   Google Scholar
• Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 Suppl 1):82–91.
   Google Scholar
• Beegle SH, Barba K, Gobunsuy R, et al. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther. 2013;7:325–338.
   Google Scholar
• Marmor MF, Kellner U, Lai TY, et al., American Academy of O. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–1394.
   Google Scholar
• Page RL 2nd, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134(6):e32–69.
   Google Scholar
• Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford). 2008;47(3):378–379.
   Google Scholar
• Unubol M, Ayhan M, Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol. 2011;17(1):46–47.
   Google Scholar
• Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J. 2014;43(6):1730–1739.
   Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.
   Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189–1196.
   Google Scholar
• Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of Adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–773.
   Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–1307.
   Google Scholar
• Rossman MD, Newman LS, and Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201–208.
   Google Scholar
• Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128(2):1062.
   Google Scholar
• Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–185.
   Google Scholar
• Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(1):70–74.
   Google Scholar
• Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–720.
   Google Scholar
• Milman N, Graudal N, Loft A, et al. Effect of the TNF-alpha inhibitor Adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012;6(4):238–247.
   Google Scholar
• Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of Adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46–54.
   Google Scholar
• Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum. 2017;47(2):288–294.
   Google Scholar
• Adler BL, Wang CJ, Bui TL, et al. Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum. 2019;48(6):1093–1104.
   Google Scholar
• Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000;59(6):1341–1359.
   Google Scholar
• Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121–139.
   Google Scholar
• Harzallah I, Rigaill J, Williet N, et al. Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therap Adv Gastroenterol. 2017;10(1):89–100.
   Google Scholar
• Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000;34(2):161–164.
   Google Scholar
• [package Insert]. Abott Laboratories NC, IL. Adalimumab; 2011 [cited 2021 Jul 20]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/adalabb123102LB.htm
   Google Scholar
• Saketkoo LA, Baughman RP. Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol. 2016;12(8):817–825.
   Google Scholar
• Vorselaars AD, Crommelin HA, Deneer VH, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175–185.
   Google Scholar
• Drent M, Cremers JP, Jansen TL, et al. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91–107.
   Google Scholar
• Puyraimond-Zemmour DC-AC, Bouvry D, Ruivard M, et al. Efficacy and tolerance of TNF alpha inhibitor treatment in cardiac sarcoidosis. Int J Exp Clin Res. 2018. DOI:10.29011/IJEACR-121.000021
   Google Scholar
• El Jammal T, Jamilloux Y, Gerfaud-Valentin M, et al. Refractory sarcoidosis: a review. Ther Clin Risk Manag. 2020;16:323–345.
   Google Scholar